Bipartisan Bill Aims To Deem Pharma Tactics Anti-Competitive

Two techniques that lawmakers say brand-name pharmaceutical companies use to keep out generics companies could become enshrined in federal law as anti-competitive business practices if Sens. Richard Blumenthal and John Cornyn...

Already a subscriber? Click here to view full article